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Abrupt cessation of regular use of alcohol in a dependent person causes a with- 
drawal syndrome that may range from mild to extremely severe. Most patients 
require pharmacologic intervention, especially. those with severe symptoms. 
Historically, the pharmacotherapy of alcohol withldrawal has involved a wide variety 
of agents. Benzodiazepines are currently preferred due to their consistently high 
degree of efficacy and laudable record of safety. In addition, I3 blockers and 
clonidine are useful, as both effectively combat the hypertension and tachycardia 
commonly associated with withdrawal. They are ineffective as anticonvulsants; 
however. Opinions differ concerning the best treatment for withdrawal seizures. 
Prophylaxis with benzodiazepines may be all that is required, although some 
authors advocate the use of phenytoin for 5 days, especially in persons with a 
history of prior seizures during alcohol withdrawal. Once established, delirium 
tremens are difficult to treat. Benzodiazepines are most commonly used to provide 
sedation, and extremely large doses may be required. Careful clinical assessment 
is essential to the proper treatment of patients undergoing alcohol withdrawal 
since the coexistence of medical problems may complicate the condition. 
(Pharmacotherapy 1989;9(3):131-143) 
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Alcohol abuse is a widespread problem in West- 
ern society, implicated in at least 50% of single- 
vehicle traffic accidents in the United States.' It is 
also a predisposing factor to death from medical 
causes such as pancreatitis,2-3 damage to the liver 
resulting in cirrhosis and esophageal varice~,~, and 
cardiac failure.6 Abrupt cessation of intake frequent- 
ly results in a withdrawal syndrome that ranges in 
severity from very mild to fatal. 
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The natural progression of the alcohol (in this re- 
view, ethanol exclusively) withdrawal syndrome was 
studied by two groups of researchers in the 1950s 
and 1960s. Alcohol was administered to 10 ade- 
quately nourished morphine addicts for varying pe- 
riods of time, to determine if an alcohol withdrawal 
syndrome would occur in the absence of nutritional 
defi~iency.~ Of the 10 patients originally entering the 
study, 4 dropped out after 34 or fewer days of con- 
tinuous alcohol ingestion. All experienced mild with- 
drawal symptoms consisting of tremulousness, nau- 
sea, perspiration, and insomnia. The remaining six 
patients drank for periods ranging between 48 to 87 
days. On withdrawal all developed tremors, marked 
weakness, nausea, vomiting, diarrhea, fever, and 
hypertension. Two experienced seizures, two had 
transient visual or auditory hallucinations or both, 
and three developed delirium tremens. The authors 
concluded that withdrawal symptoms are related to 
the duration of alcohol ingestion rather than a specif- 
ic nutritional deficiency. 
In another study 10 prison inmates with prior his- 
tories of alcoholism received 86 proof (43%) alcohol 
for 24 days6 The amount was increased daily in a 
stepwise manner, ending with 40 ounces per day 
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Table 1. Alcohol Withdrawal Symptoms 
Symptom Last Drink Usual Duration 
Vivid dreams, insomnia As alcohol leaves the body 48 hrs 
Tremor, nausea and/or vomiting, 
tachycardia ( >  110 bpm), 
hypertension (< 150/90) Within 6-24 hrs 48 hrs 
Hallucinations Variable Variable 
Convulsions 6-48 hrs Usually 1-2 grand mal-type con- 
Delirium tremens Day 3-5 2-3 days 
Usual Time of Onset After 
vulsions (although can be more 
numerous and possibly fatal) 
aData derived from references 7, 8, and 9. 
during the last 6 days. After alcohol ingestion was 
abruptly discontinued on day 24, eight subjects de- 
veloped withdrawal symptoms within 24 hours. 
Tremor and hyperreflexia occurred first. Four sub- 
jects experienced visual hallucinations within 24 
hours of discontinuing alcohol. Most had episodes 
of mild tachycardia, occurring frequently within 3-8 
days after stopping drinking. Most were also anorex- 
ic for the first 2 days of withdrawal, although no 
nausea and or vomiting was reported. This study 
provided a useful clinical description of mild to mod- 
erate alcohol withdrawal syndrome, but factors oth- 
er than the duration of continuous intake appeared 
to account for the severity of the symptoms. 
Clinical Features 
The clinical manifestations of alcohol withdrawal 
range from mild to severe (Table 1). Symptoms de- 
veloping as the alcohol concentration in the body 
decreases include insomnia and vivid dreams. With- 
in several hours after stopping drinking symptoms 
typically include anxiety, mild agitation, anorexia, 
tremor, sleeplessness, mild tachycardia (> 1 10 
beatshin), hypertension (blood pressure > 150/90 
mm Hg), diaphoresis, and nausea and vomiting. 
These symptoms usually peak between 24 and 36 
hours and may disappear after 48 hours. It is often 
stated that the relationship between the blood alco- 
hol level and the severity of the alcohol withdrawal 
syndrome is more closely related to the rapidity of 
the level’s fall than its height at the onset of with- 
drawal. 
Hallucinations 
Hallucinations unrelated to the presence of delir- 
ium tremens may occur in 3-1 0% of patients during 
They are most likely to be visual, 
although they may be auditory, tactile, or even olfac- 
tory. Both duration and onset of the hallucinations 
are highly variable. They can occur within hours of 
the last drink and have been reported while the pa- 
tient is still drinking, but typically begin after several 
days of abstinence. The hallucinations may last only 
hours, persist for weeks, or even on occasion be- 
come permanent. Patients are rarely disoriented 
and may retain the ability to recall the hallucinations 
at a later date.’* Since the content and intensity of 
these hallucinations may be similar to those seen in 
 schizophrenic^,'^ an accurate history of previous al- 
cohol use is essential for proper diagnosis. 
Withdrawal Seizures 
Withdrawal seizures or “rumfits” occur within 6-48 
hours of alcohol cessation or decrease in intake. 
They generally consist of one or two grand ma1 sei- 
zures, and rarely develop into status epi1epti~us.l~ A 
careful differential diagnosis should be entertained, 
as withdrawal seizures may be hastened by underly- 
ing pathologic states such as previous head injury 
and epilepsy. They are not usually associated with 
an epileptic focus on postictal electroencephalo- 
gram (EEG).15-16 If the patient has not previously 
been evaluated, an EEG performed during and after 
recovery from the seizure will help rule out idiopathic 
epilepsy. Focal seizures during withdrawal are un- 
usual and deserve further evaluation to rule out 
space-occupying lesions or a seizure focus secon- 
dary to head trauma. The possibility of simultaneous 
withdrawal from numerous drugs should always 
be considered. Therefore, a serum or urine toxicol- 
ogy screen is appropriate in all of these patients. 
Status epilepticus may be associated with meningi- 
tis, head trauma, cowithdrawal from sedative hyp- 
notic agents, or epi1ep~y.l~ 
Seizures occur in between 5 and 15% of patients 
undergoing withdrawal and their likelihood in- 
creases with the duration of alcohol a b ~ s e . ~ . ’ ~  Their
etiology is unknown, although a so-called kindling 
model was hypothesized18 in which withdrawal re- 
sults in hyperirritability providing low-intensity elec- 
trical stimulus of the central nervous system. Sei- 
zures may occur after numerous withdrawal 
episodes. There is some evidence to support this 
theory, as the drop in seizure threshold during with- 
drawal has been shown to be directly related to the 
duration of alcohol inge~t i0n. l~ 
Delirium Tremens 
Delirium tremens (DTs) is the most severe mani- 
TREATMENT OF ALCOHOL WITHDRAWAL Guthrie 133 
festation of this syndrome. It occurs in less than 5% 
of patients hospitalized for alcohol ~ i thdrawal .~ Sei- 
zures frequently precede DTs and rarely follow its 
onset; however, the occurrence of seizures does 
not automatically indicate that DTs will follow. Onset 
is usually on the third to fifth day of withdrawal, al- 
though the range is large.9 In one study DTs lasted a 
mean of 56 hours, with a range of 10-1 50 hours.z0 
The key symptoms are disorientation, confusion, 
visual hallucinations, and profound autonomic hy- 
perarousal. Patients may also be hyperpyrexic, 
tremulous, incontinent, and diaphoretic. As a result, 
they often are unable to feed themselves or take oral 
medication. Because of the extreme agitation that is 
frequently observed, patients often require physical 
restraints not only for their safety but for the safety of 
the hospital staff as 
Early withdrawal manifestations are reversible 
and much more readily treated than DTs.~O Patients 
with DTs are frequently febrile, agitated, and disori- 
ented, and thus concurrent illnesses such as pneu- 
monia and encephalopathy may be difficult to diag- 
nose. 
Early in this century, mortality for patients experi- 
encing untreated DTs was estimated to be as high 
as 15%; the current estimate is approximately 
2%.90zz This is almost certainly due to earlier and 
more appropriate supportive and pharmacologic 
management. Patients at greatest risk of dying are 
those older than 45 years who have concomitant 
medical or surgical illness such as fever (> 104"F, 
40"C), pneumonia, pancreatitis, malnutrition, dehy- 
dration, electrolyte imbalance, trauma, or hemor- 
rhage.z1-z3s24 Death most often results from medical 
complications such as myocardial infarction, respi- 
ratory arrest, or sepsis. 
Treatment 
Therapeutic objectives guiding the treatment of 
alcohol withdrawal include providing symptomatic 
relief and preventing medical complications. Al- 
though nonpharmacologic means may achieve the 
former, drug therapy is almost always required to 
meet both objectives. In addition, these patients are 
almost always more uncomfortable without some 
form of medication. Patients undergoing severe 
withdrawal and those with concomitant medical or 
surgical complications almost always require phar- 
macotherapy and always must be admitted to the 
hospital. Persons experiencing mild withdrawal may 
respond to nonpharmacologic therapy but pru- 
dence usually dictates hospital admission for careful 
observation. 
Nonpharmacologic Intervention 
Several groups have investigated the efficacy of 
nonpharmacologic intervention in alcohol withdraw- 
al.110z5.26 Such measures as reassurance, reality ori- 
entation, monitoring signs and symptoms of with- 
drawal, and general nursing care are frequently 
sufficient. It is important, however, to assess these 
patients carefully and manage them vigorously 
when necessary, and not run the risk of undertreat- 
ing them. 
A randomized, placebo-controlled trial was con- 
ducted in 41 withdrawing alcoholics.z6 Half received 
supportive care plus 2 mg sublingual lorazepam ev- 
ery 2 hours for a total of 3 doses; the rest received 
supportive care with sublingual placebo. The treat- 
ment was judged successful if the score on the clini- 
cal institute withdrawal assessment scale for alcohol 
(CIWA-A) was above 10. Treatment failures were 
more common in the placebo than in the lorazepam 
group (15% vs 4.8%), but 85% of those receiving 
placebo underwent withdrawal without pharmaco- 
logic intervention. Of three patients in the nondrug 
group who were considered treatment failures, one 
experienced a seizure and the other two had a 
CIWA-A score above 10. One patient of the 21 re- 
ceiving lorazepam had a CIWA-A score above 10. 
No patient in either group developed DTs. The rate 
of decrease in symptoms was more rapid during the 
first 2 hours in the group receiving lorazepam. 
Vitamin, and Fluid and Electrolyte Management 
Hydration during alcohol withdrawal is not usually 
necessaryz1 unless intractable vomiting or diarrhea 
is present. Withdrawal is associated with an in- 
crease in vasopressin plasma levels, which have 
been associated with an increase in brain water?' 
Aldosterone plasma levels are also elevated.z8 Con- 
sequently, overaggressive hydration is not only un- 
necessary, but could be harmful. Most patients are 
able to take sufficient fluids orally, and intravenous 
administration is rarely required. The presence of 
DTs may, however, cause severe dehydrationzi due 
to increased body temperature, diaphoresis, and 
agitation, combined with inability to take fluids oral- 
ly. In these patients, inadequate rehydration may 
result in increased mortality. 
Several vitamin deficiencies occur in alcoholics; 
for example, overt or subclinical thiamine deficiency 
has been reported in 30-80%.z9~30 Thiamine defi- 
ciency is particularly important because it has been 
associated with the Wernicke-Korsakoff syndrome. 
In its severe, classic form, it is manifested by drowsi- 
ness, confusion, ataxia, abnormal ocular move- 
ments (which include paralysis of eye muscles and 
nystagmus), and an amnestic confabulatory state. 
Milder forms clearly exist, however. While thiamine 
deficiency may occur in 30% or more of chronic 
alcoholics, the Wernicke-Korsakoff syndrome only 
occurs in 3-10%.3i Thiamine is nonetheless fre- 
quently given to withdrawing alcoholics in dosages 
of 50-100 mg daily. It is unknown if daily thiamine 
replenishment is necessary, however, most experts 
recommend that a dose of 100 mg be given initial- 
ly.2193z The abnormal ocular findings that occur with 
this deficiency reverse within 6-8 hours after emer- 
gency thiamine administrati~n.~~ The vitamin should 
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Table 2. Alcohol Withdrawal Studies 
Reference Drug Therapy Design Population Dose Outcome 
Acute withdrawal 
Benzodiazepines 
43 Cdxvsm+p Double-blind, pla- 
ce bo-controlled 
44 Cdx, chlorproma- Double-blind, pla- 
zine, hydroxy- ce bo-controlled 
zine, thiamine 
45 Cdx vs promazine Double-blind, pla- 
cebo-controlled 
Beta blockers 
46 Prop vs cdx vs cdx Double-blind, pla- 
+ Prop cebo-controlled 
47 Atenolol Double-blind, pla- 
cebo-controlled 
Carbamazepine 
iazole 
48 Carb vs chlormeth- Double-blind 
52 Carb vs barbital Double-blind 
53 Tiapride vs carb Double-blind 
54 Carb 
Clonidine 
55 Clon 
Double-blind, pla- 
cebo-controlled 
Double-blind, pla- 
ce bo-controlled 
56 Clon Double-blind, pla- 
cebo-controlled, 
crossover 
57 Clon vs chlormeth- Double-blind 
iazole 
58 Clon vs cdx Dou ble-blind 
Withdrawal seizures 
Phenytoin 
49 Phenytoin + cdx Double-blind, pla- 
vs cdx + cebo-controlled 
placebo 
70 
538 
58 
47 
101 
68 
72 
60 
105 
60 
11 
17 
47 
50 mg qid & 
25 mg qid cdx 
400mg + 
50 mg m+p 
Flexible dosing 
after 1st day 
200 or 400 mg/day 
400 or 800 mg/day 
cdx 
prom 
40 mg prop 
25 mg cdx 
40 + 25 mg prop 
+ cdx 
Dose individual- 
ized based on 
HR (none had 
greater than 100 
800 mg carb, then 
tapered over 6 
days 
Individualized 
mglday) 
600 mglday carb 
800 mg/day ta- 
pered over 7 
days 
0.1 5 mg tid ta- 
pered over 4 
days 
300-600 pg q6h 
clon 
0.2-mg doses ta- 
pered over 60 
hours 
157 Phenytoin 300 
mg/day x 5 
days 
Promazine felt to be superior by 
authors; both superior to pla- 
cebo. 
All patients improved, but cdx 
patients had fewer seizures 
and fewer developed DTs; all 
superior to placebo. 
Both drugs effective, but proma- 
zine caused worse hypoten- 
sion and more patients devel- 
oped DTs; both superior to 
placebo. 
Prop effective for HR and BP but 
caused unacceptable level of 
hallucinations; combination 
more effective than placebo. 
Atenolol patients had shorter 
hospital stay and fewer ben- 
zodiazepines; vital signs nor- 
malized more quickly with 
atenolol. 
No significant differences in rate 
of decrease of symptoms or fi- 
nal outcome. 
No significant differences, slight- 
ly more side effects in carb 
group. 
No significant differences in out- 
come, but more rapid de- 
crease in fear and hallucina- 
tions in carb group. 
Both effective but withdrawal 
symptoms decreased more 
rapidly in carb group. 
Clon had noticeable effects on 
tremor, sweating, systolic BP, 
tension, anxiety, and depres- 
sion; patients also received 
other medication. 
Clon significantly reduced HR, 
arterial BP, and overall with- 
drawal symptoms compared 
with placebo. 
All patients also received carba- 
mazepine; greater reductions 
in HR and BP for clon but 
overall clinical withdrawal 
course did not differ. 
Both drugs effective for physio- 
logic and psychologic with- 
drawal symptoms; don signifi- 
cantly better for reducing 
systolic BP and HR. 
All patients had seizure histo- 
ries; 11 in placebo & 0 pa- 
tients in phenytoin groups 
seized within 48 hours. 
TREATMENT OF ALCOHOL WITHDRAWAL Gufhrie 135 
Table 2. Alcohol Withdrawal Studies (continued) 
Reference Drug Therapy Design Population Dose Outcome 
50 Phenytoin + cdx Placebo-controlled 200 Phenytoin 200 mg No patients in either expe- 
vs placebo + bid x 5 days rienced seizures 
cdx 
Delirium tremens 
Benzodiazepines 
20 Diazepam vs paral- Randomized 34 Diazepam 10 mg Both drugs calmed patients but 
dehyde i.v. then 5 mg paraldehyde was associated 
i.v. q 5 min until 
calm, or paralde- died. 
hyde 10 ml by 
rectum q30 min 
until calm 
with apnea in 4, 2 of whom 
51 Diazepam vs barbi- Double-blind 91 Diazepam up to No difference in milder with- 
tal 200 mg/day, drawal, but barbital superior in 
barbital up to 5 fully developed DTs. 
Cdx = chlordiazepoxide; m + p = meprobamate plus promazine; prop = propranolol; clon = clonidine; HR = heart rate; BP = blood 
pressure. 
be administered prior to intravenous glucose, as it is 
a cofactor necessary for glucose metabolism. In an 
already thiamine-deficient patient, intravenous glu- 
cose alone can precipitate a dramatic fall in plasma 
thiamine levels. Indeed, severe and irreversible 
cerebellar and brain stem damage has been report- 
ed when glucose was administered to withdrawing 
alcoholics without concomitant thiamine. 
Deficiencies of folic acid, pyridoxine, and nicotinic 
acid are also common in alcoholics, although B, 
deficiency is rare.z9*31*s In addition to malnutrition, 
thiamine and folic acid deficiency may result from an 
alcohol-induced decrease in intestinal absorption of 
these nutrients or a genetic abnormality in transke- 
tolase, the enzyme that uses thiamine as a cofac- 
tor.34-36 If these or other vitamin deficiencies are 
present they should be corrected specifically. Al- 
though their value is unproved at present, multivita- 
min preparations are often given to these patients. 
They are certainly not likely to be harmful, and may 
be helpful. 
Total-body levels of magnesium, calcium, phos- 
phate, and zinc may be reduced. This may be due to 
decreased intake as well as increased urinary 
losses associated with alcohol i n g e ~ t i o n . ~ ~ ~ ~ ~ ~ ~ ~  
Many withdrawing alcoholics have hypomagnese- 
mia associated with respiratory alkalosis, and it was 
hypothesized that this might cause the development 
of D T S ~ ~ ;  however, such does not appear to be the 
41 Hypomagnesemia can be corrected with 
magnesium sulfate 2 g every 6 hours intravenously 
for the first day of withdrawal,z1 assuming renal func- 
tion is intact. Magnesium may be difficult to replen- 
ish with any rapidity using oral magnesium prepara- 
tions because they cause diarrhea. 
Hypokalemia may also be present, especially in 
patients suffering D T S . ~ ~  It should be corrected as 
soon as possible to avoid cardiac arrhythmias. 
Some patients may also exhibit decreased plasma 
bicarbonate, but severe acidosis should prompt a 
search for complicating factors, such as ethylene 
glycol ingestion. 
Drug Therapy 
In general, many of the studies evaluating the effi- 
cacy of pharmacotherapy for alcohol withdrawal are 
poorly designed. A review of the currently available 
literature revealed that of the 89 papers published in 
English since 1954, only 29 randomized their sub- 
j e c t ~ . ~ ~  Most of these 29 studies contained other 
design deficiencies, such as highly subjective end 
points, no listing of exclusion criteria or dropouts, 
and no blinding of patients and physicians. Al- 
though more recent trials are better designed, many 
of their conclusions are based on the older, more 
poorly designed studies (Table 2). 
Alcohol itself can be used to treat its own with- 
drawal syndrome. Most commonly this is the meth- 
od chosen by alcoholics when symptoms occur. 
However, the ingestion of relatively large amounts59 
at frequent intervals is required to maintain a blood 
alcohol level of approximately 80 mg %. The amount 
then must be gradually decreased to zero. Alcohol 
follows Michaelis-Menten pharmacokinetics, and 
predicting dosage requirements is difficult. To com- 
plicate management further, the maximum concen- 
tration of alcohol that can be given intravenously is 
about 8%, and oral alcohol may aggravate gastroin- 
testinal complaints.60. 61 Other agents are clearly 
easier and safer to use. 
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Alcohol ingestion alters the clearance of many 
drugs that are metabolized hepatically, including 
those used to treat manifestations of alcohol with- 
drawal, such as phenytoin and chlormethiazole.62 
Short-term ingestion results in decreased clearance 
of many drugs while alcohol is in the body, and 
increased clearance once it has been eliminated 
from the body of a chronic user. In the case of a drug 
with a wide therapeutic range, such as diazepam, 
this is not of paramount importance. In the case of 
one with a narrow therapeutic range, however, such 
as phenytoin, this may assume great importance, 
since a small alteration in plasma concentration may 
result in a large difference in efficacy or toxicity. 
Effective control can be achieved with agents that 
exhibit cross-tolerance to alcohol, such as the ben- 
zodiazepines, barbiturates, or nonbarbiturate hyp- 
nosedatives like paraldehyde and chlormethiazole. 
In addition, drugs such as clonidine, O-adrenergic 
antagonists, and carbamazepine, which do not ex- 
hibit cross-tolerance with alcohol, also appear to be 
effective. 
Benzodiazepines 
High-affinity stereospecific receptors for benzo- 
diazepines have been identified in the mammalian 
central nervous 64 Binding of a benzodia- 
zepine to its receptor appears to potentiate the phar- 
macologic actions of y-aminobutyric acid (GABA) 
through actions at the benzodiazepine-GABA-chlo- 
ride channel complex. Alcohol is thought to alter the 
binding of the benzodiazepine to its receptor.65 In- 
teractions at this receptor complex may be the basis 
for benzodiazepine-alcohol cross-tolerance. 
Benzodiazepines are now the standard treatment 
for symptoms of alcohol withdrawal, although the 
belief that they are more effective than placebo is 
based on old and rather badly designed s t u d i e ~ . ~ ~ - ~ ~  
This class of drugs has superior anticonvulsant ac- 
tivity combined with a higher therapeutic index and 
ease of use when compared with other agents such 
as paraldehyde and barbiturates. Although they all 
do not have specific indications for alcohol with- 
drawal, many different benzodiazepines have been 
successfully used, including chlordiazepoxide, dia- 
zepam, lorazepam, oxazepam, clobazam, cloraze- 
pate, alprazolam, bromazepam, and fluraze- 
pam.66*67 They all possess anticonvulsant, 
antianxiety, and sedative effects that are effective in 
this condition.68 Unfortunately, they are not effective 
in withdrawal hallucinations. Their potencies, onset 
of effect, and metabolic pathways clearly differ 
(Table 3). 
The most widely studied agents are chlordiaze- 
poxide and diazepam. Chlordiazepoxide has been 
shown to be more effective than placebo or no drug 
therapy in decreasing seizure frequency, restless- 
ness, anxiety, tremor, and the development of 
DTs.~’ Both diazepam and chlordiazepoxide are bio- 
transformed to desmethyldiazepam, a long-lived, 
active metabolite, and continuous dosing results in 
its accumulation. If this is not taken into consider- 
ation, excessive drowsiness, confusion, diplopia, 
ataxia, and sedation may occur. To avoid toxicity, 
large initial doses are often administered on the first 
day of withdrawal (e.g., chlordiazepoxide 100 mg or 
diazepam 20 mg titrated acutely to the patient’s clini- 
cal state) until the patient is appropriately sedated. 
Both should be administered orally when possible, 
or intravenously if necessary, but intramuscular ad- 
Table 3. Characteristics of Benzodiazepines Used in the United States” 
Elirnina- 
tion Half- Clinically Important 
Benzodiazepine Onset After Oral Dose Life (hrs) Metabolites 
Oxidatively metabolized 
C hlordiazepoxidea Intermediate 10-30 N-desrnethylchlordiazepoxide 
N-desmethyldiazeparn 
Dernoxeparn 
Diazepama Rapid 20-80 N-desrnethyldiazepam 
Oxazepam 
Flurazeparn Rapid to intermediate 2.3 N-desal kylfl u razeparn 
Prazeparn Slow 1.1 N-desrnethyldiazepam 
Alprazolarn Intermediate 10-1 2 None 
Halazeparn Intermediate to slow 14 N-desrnethyldiazepam 
Triazolam Intermediate 2-4 None 
Clorazepatea Rapid Prodrug N-desrnethyldiazeparn 
Oxazeparna Intermediate to slow 6-1 2 None 
Lorazeparn Intermediate 7-35 None 
Temazeparn Intermediate to slow 6-13 None 
Half-life of metabolites: N-desmethylchlordiazepoxide 16 hrs; N-desmethyldiazepam 50-200 hrs; N-desalkylflura- 
aApproved FDA indication for alcohol withdrawal. 
Data derived from references 69 and 70. 
Conjugated 
zepam >lo0 hrs; demoxepam 40 hrs. 
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ministration should be avoided, Doses are reduced 
to 25-50% of initial doses in a stepwise fashion on 
subsequent days.66. 71 Several treatment regimens 
for different benzodiazepines have been used, 
some of which are listed in Table 4. 
A variation of the stepwise reduction strategy uses 
the long half-life of desmethyldiazepam and gives 
loading doses of diazepam 20 mg every 1-2 hours 
on the first day of ~ i t hd rawa l .~~  (In this study a medi- 
an of 60 mg was given over 7.6 hours.) Dosing is 
titrated by clinical assessment of the patient at hour- 
ly intervals. This strategy affords the presence of a 
tapering plasma concentration of active drug over 
the entire withdrawal period of approximately 1 
week. 
Drugs with a long half-life are also useful for the 
large number of patients who refuse to stay in the 
hospital for the full course of therapy. Although any 
of the benzodiazepines may be used for symptom- 
atic relief of withdrawal, those without active metab- 
Table 4. Benzodiazepine Dosing Options in Acute 
Alcohol Withdrawal 
Regirnan (oral unless 
Drug otherwise stated) Reference 
Diazepam 
~ 
Chlordiazepoxide Day 1 100 rng q6h 46 
Day 2 100 rng q8h 
Day 3 100 rng q12h 
Day 4 100 rng hs 
Day 1 50rng q8h + 50 72 
rng x 1 
Day2 50 rng q8h 
Day3 25 rng q8h 
Day 4 25 rng bid 
Clorazepate Day 1 30 rng initially, fol- 73 
lowed by 15 
rng bid 
Day 2 15 rng tid 
Day 3 15 rng bid 
Day 4 7.5 rng tid 
Day 5 7.5 rng bid 
Day 1 10 rng tid 74 
Day 2 10 rng, 5 rng, 10 
Day3 5 rng tid 
Day 4 5 rng bid 
Day 1 20 rng initially, fol- 17 
lowed by 20 
rng q2h until 
reaction con- 
trolled 
x l  
rng 
Loraze pam Day1 2rngq8h+2rng 72 
Day2 2rng q8h 
Day3 1 rng q8h 
Day 4 1 mg bid 
Day 2 Average daily 
oral dose 2 or 3 
rng continued 
as long as 
needed 
Day 1 5 rng i.rn. 75 
olites, such as oxazepam or lorazepam, must be 
dosed more frequently. 
The use of benzodiazepines with a short half-life 
has been advocated in patients with possible hepat- 
ic dysfunction because these agents are not de- 
pendent on hepatic enzymatic metabolism, as they 
are generally glucuronidated rather than oxidatively 
metabolized. There is no convincing evidence that 
these agents are better tolerated than those with a 
long half-life when they are administered using a 
regimen that avoids long-term dosing and accumu- 
lation of active metabolites, such as the loading 
dose protocol described above. In the event that 
patients cannot take oral medication, lorazepam 
may be preferred, since it is available in a parenteral 
form that is completely absorbed intramuscular- 
ly.77. 78 Chlordiazepoxide is erratically absorbed 
when given intramuscularly, and the absorption of 
intramuscular diazepam varies depending on the 
site of 79 
B Blockers 
Elevated plasma and urinary concentrations of 
norepinephrine have been documented during al- 
cohol withdrawal and symptoms such as tachycar- 
dia, hypertension, and tremors are probably due to 
increased noradrenergic activity.80-81 Benzodiaze- 
pines, although effective against many withdrawal 
symptoms, do not possess any direct antiadrener- 
gic effects.46 In an investigation of hand tremor in 
alcoholic withdrawal, propranolol caused a 95% de- 
crease in tremor magnitude.82 A double-blind, pla- 
cebo-controlled clinical trial randomized 60 patients 
to four different groups: placebo, chlordiazepoxide 
25 mg every 6 hours for 24 hours, propranolol40 mg 
every 6 hours for 48 hours, or propranolol combined 
with chl~ridiazepoxide.~~ Cardiac response was 
measured by ambulatory electrocardiogram. During 
the first 12-24 hours both propranolol and the com- 
bination decreased total arrhythmias and blood 
pressure more effectively (p < 0.05) than chlordi- 
azepoxide alone. However, the dose of chlordiazep- 
oxide was quite low. Four (27%) of 15 patients who 
received propranolol alone experienced hallucina- 
tions compared to none who received placebo or 
chlordiazepoxide. The occurrence of hallucinations 
secondary to propranolol administration is typically 
rare,83 but appears to be increased during alcohol 
withdrawal. 
Atenolol has been recently advocated in the treat- 
ment of alcohol withdrawal. When heart rate was 
50-79 beatshinUte patients received atenolol 50 
mg daily; when it was 80 beatshinUte they received 
10 mg or a look-alike placebo. The length of hospital 
stay was significantly reduced for those receiving 
atenolol (p < 0.02), and vital signs (heart rate, blood 
pressure, temperature) returned to normal more 
rapidly.47 The baseline clinical severity scores were 
never reported for this study, although the authors 
state that the patients were undergoing mild to mod- 
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erate alcohol withdrawal. There was no evidence of 
adverse effects in the atenolol group, including hal- 
lucinations. The decreased lipophilicity of atenolol 
should result in decreased accumulation in the cen- 
cause some severe side effects, such as hematolog- 
ic or dermatologic reactions. 
Clonidine 
tral nervous system compared with pr~pranolo l .~~ 
Although atenolol’s effects on vital signs were sig- 
nificantly greater, no significant differences were 
noted between atenolol and placebo with respect to 
clinical features (tremor, seizures, level of con- 
sciousness) or behavioral signs (anxiety, agitation, 
hallucinations). Because 0 blockers cannot be ex- 
pected to have significant effects on anxiety or sei- 
zures, a benzodiazepine will probably still be re- 
quired in conjunction with a 0 blocker for the 
optimum treatment of alcohol withdrawal. 
Ca rbamazepine 
Carbamazepine has been used extensively in 
Scandinavia for the treatment of alcohol withdrawal, 
but only four double-blind trials have been conduct- 
ed. The drug was compared with chlormethiazole in 
68 patients, with 34 randomly assigned to each 
treatment group.48 The initial daily doses of carba- 
mazepine and chlormethiazole were 800 and 2400 
mg, respectively, and doses of both drugs were ta- 
pered over a 7-day period. No significant differences 
were reported between the groups in either the rate 
of decrease of withdrawal symptoms or final out- 
come. A Danish group5, compared carbamazepine 
(n = 37) with barbital (n = 35) in 72 inpatients 
undergoing mild to moderate alcohol withdrawal. 
The duration of treatment and the dosages were 
individualized based on clinical judgment. No statis- 
tically significant differences were recorded in the 
rate of decrease of withdrawal symptoms, ultimate 
outcome, or patients’ subjective evaluations. The 
group receiving carbamazepine reported slightly 
more side effects (dizziness and nausea). 
Carbamazepine or tiapride was administered to 
60 “predelirium” inpatients for 7 days.53 Withdrawal 
symptoms, especially fear and hallucinations, were 
relieved more rapidly in the group receiving carba- 
mazepine 600 mg/day, fixed dose, but the outcome 
was the same in both groups. In the only placebo- 
controlled, multicenter study, 105 outpatients un- 
dergoing mild to moderate alcohol withdrawal were 
randomly assigned to receive carbamazepine 800 
mg initially and tapered over 7 days, or placebo.” 
Although both treatments were effective, symptoms, 
including tremor, diaphoresis, tachycardia, anorex- 
ia, restlessness, and anxiety, improved more rapidly 
in the group receiving carbamazepine on days 2 (p 
0.01) and 4 (p 0.1). Side effects associated with 
carbamazepine included nausea, vomiting, and diz- 
ziness. 
Carbamazepine appears to be as effective as bar- 
bital, tiapride, and chlormethiazole. Since these 
agents are not available in the United States, howev- 
er, a study comparing carbamazepine with a benzo- 
diazepine would be helpful. Carbamazepine does 
not lead to dependence but it may occasionally 
Five studies have been conducted using cloni- 
dine in the treatment of alcohol withdrawal. The in- 
creased noradrenergic activity present during with- 
drawal is associated with not only cardiovascular 
symptoms, but also tremulousness, anxiety, dia- 
phoresis, and insomnia.85 Clonidine acts centrally 
as an a,-receptor agonist, causing a reduction in 
norepinephrine release in the locus ceruleus. 
Using a double-blind design, a tapering dose of 
oral clonidine 0.1 5 mg 3 times daily on the first day 
and reduced by 1 dose daily, was compared with 
placebo in 60 withdrawing a lcohol i~s.~~ On day 2 of 
treatment those receiving clonidine reported signifi- 
cantly reduced tension, tremor, anxiety, palpita- 
tions, and restlessness. The results of this study are 
confounded, however, because the patients in both 
groups had also received other medications includ- 
ing phenytoin, chlorpromazine, and a hypnotic con- 
taining diphenhydramine and methaqualone. In an- 
other study, the effects of clonidine were compared 
with placebo in 1 1 patients with well-developed with- 
drawal ~ y m p t o m s . ~ ~  Clonidine significantly de- 
creased not only heart rate and blood pressure, but 
also subjective anxiety. 
Withdrawal symptoms were significantly sup- 
pressed by clonidine compared to chlormethia- 
zole.86 Another comparison of these agents (n = 9 
and 8, respectively) recorded significantly greater 
reductions of blood pressure and heart rate in the 
clonidine group.57 However, the overall measure- 
ment of clinical withdrawal course (which included 
such variables as sweating, restlessness, anxiety, 
and hallucinations) did not differ between the two 
drugs. 
A recent study provides the best evidence sup- 
porting the efficacy of clonidine for the treatment of 
alcohol w i thd ra~a l .~~  Forty-seven medically stable 
alcoholic patients undergoing mild to moderate 
withdrawal were randomly assigned to receive cloni- 
dine (n = 26) or chlordiazepoxide (n = 21). Patients 
received 0.2 mg clonidine or 50 mg chlordiazepox- 
ide tapered over 4 days. All subjects received a dose 
at 9 PM on day 1; at QAM, 1 PM, and 6 PM On day2;  AM 
and 6 PM on day 3; and 9 AM on day 4. Both drugs 
caused significant decreases in systolic and diastol- 
ic blood pressures and heart rate, but the reduction 
in systolic blood pressure and heart rate was signifi- 
cantly greater with clonidine than with chlordiaze- 
poxide. There were no statistically significant differ- 
ences between the two drugs with respect to 
decreases in respiratory rate, diaphoresis, tremor, 
restlessness, or anxiety. NO major differences in ad- 
verse effects were reported between the two 
groups, except that more nausea and vomiting OC- 
curred with chlordiazepoxide. Subjects were ob- 
served for 24 hours after the final dose, and those 
receiving clonidine experienced no clinically signifi- 
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cant hypotension or rebound hypertension. 
The hypothesized mechanism of clonidine’s effi- 
cacy in alcohol withdrawal involves stimulation of 
central ap adrenergic receptors. The locus ceruleus 
(LC) is the largest collection of noradrenergic neu- 
rons in the central nervous system. Axons from neu- 
rons in the LC project into the forebrain area. The LC 
noradrenergic neurons contain a2 receptors, as well 
as opiate receptors. When these central ap recep- 
tors are stimulated, inhibition of noradrenergic out- 
put results, secondary to increased potassium con- 
ductance intracellularly and a hyperpolarization of 
the cellular membrane. Alcohol withdrawal is clearly 
associated with hyperactivity of the LC, although the 
precise mechanism is not clearly defined. The inhi- 
bition of noradrenergic firing in the LC produced by 
clonidine and other a2 agonists putatively results in 
a decrease in withdrawal effects associated with LC 
hyperactivity, such as increases in blood pressure 
and heart rate, restlessness, diaphoresis, and in- 
~ o m n i a . ~ ~  Clonidine has no anticonvulsant activity, 
however, and it is unknown if its use is associated 
with any difference in the frequency of withdrawal 
seizures compared with benzodiazepines, since the 
only study comparing these two agents excluded 
subjects with a previous history of seizures or se- 
vere withdrawal. 
Paraldehyde 
Paraldehyde used to be employed commonly for 
treatment of the alcohol withdrawal syndrome. As 
the benzodiazepines have gained in popularity, its 
use has diminished sharply. Paraldehyde exhibits 
complete cross-tolerance with alcohol and, as such, 
is as effective in the treatment of withdrawal as the 
barbiturates and benzodiazepines.88 Although par- 
aldehyde is an effective sedative and prevents pro- 
gression to withdrawal seizures or DTs when used 
early in the course of withdrawal, it is much more 
toxic than the benzodiazepines.20 Tolerance also 
develops quickly, and weaning patients from the 
drug is often difficult. Administration is problematic 
because intramuscular injection frequently results in 
local irritation and may progress to the formation of 
sterile abscesses. Intravenous injection has less 
commonly been associated with pulmonary ede- 
ma.71,88 Paraldehyde may be given orally or rectally, 
but rectal administration may result in proctitis or 
slow and erratic absorp t i~n .~~ Because of its irritat- 
ing nature, paraldehyde should always be mixed 
with 60-100 ml olive or mineral oil prior to rectal 
instillation. In addition, its pharmacologic action is 
short so it must be dosed freq~ently.~’ 
Other Agents 
Phenothiazines and butyrophenones have both 
been reported to be as effective as chlordiazepoxide 
in the treatment of alcohol withdrawal.43~44*90~91 All of 
these studies are quite old, and numerous faults can 
be found with their designs; consequently, consid- 
erable doubt remains concerning the comparable 
efficacy of these agents. This may be a minor point 
since there is no doubt that the neuroleptics are 
more toxic than benzodiazepines. They lower the 
seizure threshold, and their use in alcohol withdraw- 
al has resulted in an increased frequency of sei- 
z u r e ~ . ~ ~  The drugs also possess other undesirable 
pharmacologic side effects. Their a,-adrenergic re- 
ceptor-blocking effects can cause considerable or- 
thostatic hypotension, their anticholinergic effects 
can result in anticholinergic delirium at high doses, 
and they can interfere with thermoregulation. They 
are also capable of causing extrapyramidal move- 
ment disorders and the neuroleptic malignant syn- 
drome. 
Neuroleptics are not generally recommended be- 
cause of their side effects and their questionable 
efficacy. Nonetheless, haloperidol is occasionally 
used, always in conjunction with a benzodiazepine, 
for the treatment of hallucinations that are not re- 
sponsive to benzodiazepines alone.17-66~92 Small 
doses (0.5-2 mg intramuscularly) are typically 
used.lg The use of haloperidol without a benzodiaz- 
epine in alcohol withdrawal is not recommended 
since it lowers seizure threshold. 
Barbiturates were frequently employed in the 
treatment of this syndrome prior to the advent of the 
benzodiazepines. They can no longer be recom- 
mended even though they have proven anticonvul- 
sant activity and can effectively control the withdraw- 
al reaction. Their therapeutic index is much too 
narrow, they cause hepatic enzyme induction, and 
their abuse potential is high.66-88 
Chlormethiazole is administered for this syn- 
drome in many countries outside the United States. 
Its chemical structure is similar to that of thiamine, 
although this has no bearing on its pharmacologic 
effect. It possesses sedative-hypnotic as well as an- 
ticonvulsant effects. It is considerably more toxic 
than benzodiazepines and, in high doses, it pro- 
duces marked respiratory depression combined 
with increased bronchial ~ecre t ion .~~ Elimination 
from the body is fairly rapid, with a plasma half-life of 
4-6 hours; thus it requires frequent dosing.94 Ironi- 
cally, chlormethiazole’s bioavailability is increased 
when it is administered with and it has 
been associated with successful suicide attempts 
when taken with a l c o h 0 1 . ~ ~ ~ ~ ~  
Hydroxyzine, a sedative antihistaminic agent, has 
also been employed for symptomatic relief of alco- 
hol withdrawal. Its efficacy as an anxiolytic is ques- 
tionable and it does not possess anticonvulsant ac- 
t i ~ i t y . ~ ~ , ~ ~  In addition, large doses may result in 
anticholinergic toxicity, which is often manifested as 
confusion, disorientation, urinary retention, halluci- 
nations, and tachy~ardia.~~ These side effects may 
be difficult to distinguish from those caused by the 
withdrawal syndrome itself, and in any case they are 
undesirable reactions in this population. 
Although many pharmacologic agents have been 
used to allay the symptoms of alcohol withdrawal, 
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Table 5. Drugs Used in Alcohol Withdrawal 
Toxicity: 
Anti- Anxiolysisl Safety 
Drug convulsant Sedation Ratio 
Anti histamines 
Barbiturates 
Benzodiazepines 
D blockers 
Carbamazepine 
Chlormethiazole 
Clonidine 
Haloperidol 
Paraldehyde 
Phenothiazines 
- 
+ + +  
+ +  
0 
+ + +  
+ +  
0 
- I0 + +  
- 
+ 
+ + +  
+ + +  
+ 
+ +  
+ +  
+ 
+ 
+ + +  
+ +  
+ +  
+ 
+ + +  
+ +  
+ +  
+ 
+ +  
+ +  
+ 
+ 
0 = none; - = negative; + = mild; + + = moderate; 
Data derived from references 9, 20, and 22. 
+ + + = marked. 
the current drugs of choice are clearly the benzodi- 
azepines. Of the agents reviewed above, they exhib- 
it the most attractive antiwithdrawal profile (Table 5). 
Treatment of Seizures 
Most patients experiencing alcohol withdrawal 
suffer only one or two seizures,1oo and it is generally 
agreed that in most cases, they do not require pro- 
phylactic anticonvulsant therapy. Some authors 
claim that prophylaxis with benzodiazepines is suffi- 
cient to prevent seizures.44- 50 Phenytoin is common- 
ly used although its prophylactic efficacy in the sei- 
zures of withdrawal is not well-established. 
Using a placebo-controlled design, phenytoin 
300 mg/day orally was administered in combination 
with sedative doses of oral chlordiazep~xide~~ to 
157 withdrawing alcoholics. The chlordiazepoxide 
dosage was determined on an individual basis by 
the nursing staff, but on average it was 400 mg in the 
first 24 hours, 200 mg in the second 24 hours, and 
none after the fourth day. All patients had a history of 
seizures during adult life (no distinction was made 
between seizures of alcohol withdrawal and other 
disorders). Within the first 48 hours 1 1 patients in the 
placebo group, but none in the phenytoin group, 
experienced seizures. The authors recommended 
that phenytoin 300 mg/day be given to patients ex- 
periencing alcohol withdrawal who have histories of 
seizures. 
In a similar study in 200 patients, those randomly 
designated to the phenytoin group received 200 mg 
twice daily for 5 day~.~~Although 40 of these patients 
had histories of previous withdrawal seizures, none 
in either the placebo or phenytoin groups had such 
episodes. The author concluded that chlordiaze- 
poxide was effective in preventing seizures and that 
the addition of another anticonvulsant is unwarrant- 
ed. 
Only one group measured phenytoin plasma con- 
centrat ion~.~~ Values were all in the subtherapeutic 
range (4 p,g/ml). It is possible that the concentra- 
tions required for prophylaxis in alcohol withdrawal 
seizures may be lower than those required for epi- 
leptic seizures (i.e., 10-20 p,g/ml). It should also be 
noted that phenytoin is highly protein bound, and 
total, not unbound, plasma concentrations were re- 
ported in this study. Since the drug is bound primar- 
ily to albumin, protein binding might have been 
decreased in this population. Phenytoin’s pharma- 
cokinetics in the alcoholic population are altered by 
the effects of alcohol on hepatic metabolism. The 
agent’s clearance was increased in patients under- 
going withdrawal once drinking ceased, and the au- 
thor concluded that the standard dosage (300 
mg/day) will often result in subtherapeutic plasma 
concentrations in these patients.lol 
Most literature sources currently advise the use of 
phenytoin in withdrawing patients who are at high 
risk for seizures (i.e., those with a history of epilepsy 
or recurrent withdrawal  seizure^).^, lo2 Prophylactic 
anticonvulsant therapy is recommended for only 5 
days unless an underlying epileptic focus is pres- 
ent.9 Long-term prescribing of anticonvulsants to 
chronic alcoholics may actually increase their pre- 
disposition to seizures due to erratic compliance 
with the regimen.103*’04 Phenytoin is poorly ab- 
sorbed after intramuscular injection, and therefore 
oral or intravenous administration is recommended. 
A loading dose of 10 mg/kg may be given intrave- 
nously at a rate of 50 mg/minute to achieve ade- 
quate anticonvulsant plasma concentrations.88 Plas- 
ma concentrations should be monitored during 
maintenance dosing, since drug clearance may be 
altered in patients undergoing alcohol withdrawal. 
In addition to phenytoin, other anticonvul- 
sants that have been used to treat withdrawal sei- 
zures include h arb amaze pine,^^^ 54, lo5-lo7 valproic 
acid,108* log and primidone.l1° A retrospective study 
found the combination of primidone and chlordiaze- 
poxide (1000 patients) to be more efficacious than 
phenytoin and chlordiazepoxide (500 patients).’1° 
Little can be inferred from these data, however, as 
the trial was not randomized. The dosage of chlor- 
diazepoxide was not reported, nor was the history of 
preexisting epilepsy clearly stated. Carbamazepine 
has been evaluated in  human^^**'^^ as well as in 
ratslo6 undergoing alcohol withdrawal. Again, de- 
sign flaws in these studies preclude objective clini- 
cal interpretation. Indeed, placebo-controlled stud- 
ies measuring carbamazepine’s efficacy in alcohol 
withdrawal seizures in humans are not available. 
Valproic acid has been shown to have some efficacy 
in these seizures in  animal^,"^-'^^ but both human 
studies were retrospective chart reviews.108. 109 
Treatment of Delirium Tremens 
Delirium tremens is the most dramatic and dan- 
gerous manifestation Of acute alcohol withdrawal. 
oral medications are frequently not a viable option. 
These patients are almost always quite agitated and 
combative, and they frequently describe vivid, fright- 
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ening, threatening hallucinations, adding to their 
agitation. Once DTs are established they are not 
reversible, and the main objective of treatment is to 
provide sedation.21 Many sedative agents have 
been used to treat 114-117 and the same ad- 
vantages and disadvantages of each drug in the 
treatment of less severe withdrawal apply to this 
use. 
Paraldehyde 10 ml rectally every 30 minutes was 
compared to diazepam 10 mg then 5 mg intrave- 
nously every 5 minutes in 34 patients with DTs.~O 
Although both drugs effectively calmed the patients, 
paraldehyde proved much more toxic, causing ad- 
verse reactions in 9 of 17 patients who received it. 
Two of these patients died from unknown causes, 
one bit his nurse, another bit the physician, two de- 
veloped sudden apnea during paraldehyde induc- 
tion, one was caught while attempting to jump from 
the window, and two experienced brachial plexus 
injury secondary to violent agitation. No adverse re- 
actions occurred in the diazepam group. 
A double-blind comparison between intramuscu- 
lar diazepam and oral barbital was performed in 30 
patients experiencing D T s . ~ ~  Barbital resulted in a 
more satisfactory effect, defined as time to sedation, 
patient cooperation, and course of clinical condition. 
Evaluation of this study is difficult, however, be- 
cause the route of diazepam administration was not 
optimal, and the nursing staff was very familiar with 
barbital effects, so that the double-blind was difficult 
to maintain. 
Patients experiencing DTs may require very large 
doses of sedatives, therefore a drug with a large 
therapeutic index will always be attractive. No stud- 
ies have compared the benzodiazepines with 
agents other than paraldehyde or barbital in the 
treatment of DTs; however, the available data over- 
whelmingly support the benzodiazepines as being 
the drugs of choice. 
Summary 
While many pharmacologic agents have been 
used in alcohol withdrawal, it is important to remem- 
ber that not all patients, especially those undergoing 
mild withdrawal, require pharmacologic interven- 
tion. A full assessment of any patient undergoing 
alcohol withdrawal is necessary to detect any medi- 
cal complications and to assure that optimal phar- 
macotherapy is given, since early treatment will pre- 
vent progression to the more severe forms of 
withdrawal. It is crucial that a placebo control group, 
or, more realistically, a control group that is treated 
with a standard regimen, such as a benzodiazepine, 
be part of any study designed to evaluate the safety 
and efficacy of a new agent proffered for the treat- 
ment of mild to moderate alcohol withdrawal. Cur- 
rently, benzodiazepines represent the agents with 
the most tasteful blend of efficacy and safety. Al- 
though they are not perfect agents, in that they can 
cause somnolence and are themselves subject to 
abuse, they are clearly the best agents presently 
available. Phenytoin is currently recommended if a 
preexisting seizure disorder is present or if recurrent 
withdrawal seizures occur. 
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